Form 4 for IGC IGC Pharma, Inc.
Accepted 2022-06-28 00:00:00 ET · period of report 2022-05-31 · accession 0001185185-22-000782 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-06-28 | 2022-05-31+ | IGC | LYNCH John Edward | Dir | M - OptEx | $0.00 | +37.5K | 134.4K | +39% | $0 |
| D | 2022-06-28 | 2021-12-20 | IGC | LYNCH John Edward | Dir | A - Grant | $0.00 | +150.0K | 300.0K | +100% | $0 |
| DM | 2022-06-28 | 2022-05-31+ | IGC | LYNCH John Edward | Dir | M - OptEx | $0.00 | -37.5K | 271.9K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK | 2022-05-31 | M | A | 28,125 | $0.00 | 125,026 | D | — | — | (F1) On December 20, 2021, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved. On May 31 and June 1, 2022, two of the milestones related to our IGC-AD1 clinical trials were reached. |
| 2 | Common | COMMON STOCK | 2022-06-01 | M | A | 9,375 | $0.00 | 134,401 | D | — | — | (F1) On December 20, 2021, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved. On May 31 and June 1, 2022, two of the milestones related to our IGC-AD1 clinical trials were reached. |
| 3 | Derivative | Restricted Stock Units | 2021-12-20 | A | A | 150,000 | $0.00 | 300,000 | D | $0.00 · — to 2032-03-31 | 150,000 Common Stock | (F1) On December 20, 2021, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved. On May 31 and June 1, 2022, two of the milestones related to our IGC-AD1 clinical trials were reached. |
| 4 | Derivative | Restricted Stock Units | 2022-06-01 | M | D | 9,375 | $0.00 | 262,500 | D | $0.00 · — to 2032-03-31 | 9,375 Common Stock | (F1) On December 20, 2021, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved. On May 31 and June 1, 2022, two of the milestones related to our IGC-AD1 clinical trials were reached. |
| 5 | Derivative | Restricted Stock Units | 2022-05-31 | M | D | 28,125 | $0.00 | 271,875 | D | $0.00 · — to 2032-03-31 | 28,125 Common Stock | (F1) On December 20, 2021, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved. On May 31 and June 1, 2022, two of the milestones related to our IGC-AD1 clinical trials were reached. |